Yichang HEC Changjiang Pharma - 1558 HK

Health CareHong Kong

Refresh

bullish•Yichang HEC Changjiang Pharma•27 Nov 2022 05:15

HEC Pharma (1558 HK): Core Product Saw Volume Recovery in 1H 2022; New Launches to Accelerate Growth

HEC Pharma’s revenue jumped ~6x in 1H22, driven by volume recovery of its core drug Kewei. Going ahead, new generic launches and insulin portfolio...

Tina Banerjee

302 Views

Share

bullish•Guangzhou R&F Properties•17 Jul 2020 12:49

Full Circulation Of H-Shares - July Update

This update is the latest in a series dating back to Legend's Conversion of Domestic Shares in June 2018, with the most recent addition CPPCC And...

David Blennerhassett

525 Views

Share

bullish•Thematic (Sector/Industry)•23 Dec 2022 14:05

2022 in Rear Mirror View: Top Performers From My Global Healthcare Coverage Universe

From my coverage universe, two Taiwanese stocks generated 59% and 71% returns in nearly six months. New product launch and geography expansion are...

Tina Banerjee

658 Views

Share

bearish•Quantitative Analysis•12 Dec 2022 08:15

Hong Kong Connect Flows (Dec 9th): HKEx, Ping An H&T, Tencent, Xiaomi, Li Ning, Meituan

We analyzed southbound Hong Kong connect flows in the past week and highlight flows for HKEx, Ping An H&T, Tencent, Xiaomi, Li Ning, Meituan,...

Ke Yan, CFA, FRM

400 Views

Share

bullish•Yichang HEC Changjiang Pharma•24 Nov 2021 18:12

Yichang HEC Changjiang Pharma (1558 HK): Multiple New Products Launches Bring New Opportunities

HEC Pharm is on a new growth path through the launch of diabetes and oral HCV drugs. The company has a rich pipeline of innovative drugs, entailing...

Tina Banerjee

200 Views

Share

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v1.8.3

x